Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Ipsen
  6. News
  7. Summary
    IPN   FR0010259150

IPSEN

(IPN)
  Report
Real-time Quote. Real-time Euronext Paris - 07/30 11:38:21 am
90.1 EUR   +1.78%
12:09pIPSEN : Exceeding again our CSR-based targets
PU
07/29IPSEN : delivers strong H1 2021 results and upgrades full-year...
PU
07/29Ipsen S.A. Raises Sales Guidance for the Fiscal Year 2021
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ipsen : A year-long partnership with the ISPC

06/18/2021 | 03:15am EDT


A year-long partnership with the ISPC

This year, Ipsen is partnering with the Institut de Santé Parasport Connecté (ISPC) to sponsor Gaëlle Edon, a high-level athlete. She is also vice-president of ISPC Synergies and a member of the French shooting team.

Gaëlle is currently preparing for the Tokyo ympics this summer, as well as for the Paris lympics in 2024. Ipsen teams will support Gaëlle by participating in internal challenges and will receive a series of short inspirational videos of her training and athletic performances throughout the year, both internally and externally.

Watch Gaëlle Edon's testimonial below.

A high-level athlete in line with Ipsen's values

Beyond Gaëlle Edon's athletic prowess, it is her resilience and determination that inspired us to partner with this first-class ambassador of the 'Parasport-health' that ISPC Synergies has been promoting since its creation.

Gaëlle embodies the values that we live by every day at Ipsen: passion, ambition, tenacity and an unwavering determination to continually surpass ourselves. Ipsen's teams have put their full support behind this outstanding athlete ahead of her participation in upcoming international events and the Olympic Games. These are the shared values that drive us to put the patient at the heart of everything we do.

Disclaimer

Ipsen SA published this content on 18 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 June 2021 07:14:00 UTC.


© Publicnow 2021
All news about IPSEN
12:09pIPSEN : Exceeding again our CSR-based targets
PU
07/29IPSEN : delivers strong H1 2021 results and upgrades full-year...
PU
07/29Ipsen S.A. Raises Sales Guidance for the Fiscal Year 2021
CI
07/28GLOBAL MARKETS LIVE : Apple, Alphabet, Facebook, Pfizer, McDonald's...
07/28IPSEN : strengthens its pre-clinical Oncology pipeline with an exclusive worldwi..
AQ
07/28IPSEN : BAKX Therapeutics to Develop Cancer Treatment
MT
07/27IPSEN : BAKX collaboration-27 July 2021
PU
07/27Ipsen and BAKX Therapeutics Inc. Signs Exclusive Worldwide-Collaboration Agre..
CI
07/16GLOBAL MARKETS LIVE : Intel, Moderna, Burberry, Pfizer, SoftwareOne, Swisscom...
07/16IPSEN : and IRLAB enter exclusive worldwide licensing agreement aimed to improve..
AQ
More news
Financials
Sales 2021 2 748 M 3 260 M 3 260 M
Net income 2021 580 M 688 M 688 M
Net Debt 2021 157 M 186 M 186 M
P/E ratio 2021 12,6x
Yield 2021 1,14%
Capitalization 7 301 M 8 680 M 8 661 M
EV / Sales 2021 2,71x
EV / Sales 2022 2,53x
Nbr of Employees 5 703
Free-Float 41,9%
Chart IPSEN
Duration : Period :
Ipsen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IPSEN
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 88,52 €
Average target price 92,58 €
Spread / Average Target 4,59%
EPS Revisions
Managers and Directors
David G. Loew Chief Executive Officer & Director
Aymeric Le Chatelier Chief Financial Officer & Executive Vice President
Marc M. P. de Garidel Non-Executive Chairman
Aidan Murphy Executive Vice President-Technical Operations
Howard Mayer Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
IPSEN30.37%8 680
JOHNSON & JOHNSON9.40%453 418
ROCHE HOLDING AG12.49%335 069
PFIZER, INC.16.25%239 525
NOVARTIS AG-0.16%224 495
ELI LILLY AND COMPANY45.30%223 011